leadf
logo-loader
viewFutura Medical PLC

Futura Medical advancing commercial discussions and planning further launches

Picture of Futura Medical

Futura Medical PLC’s (LON:FUM) CEO James Barder tells Proactive’s Andrew Scott negotiations over a deal with a partner that would help commercialise their breakthrough erectile dysfunction treatment are at an advanced stage.

MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate or carry significant side-effects.

The update came a day after Futura announced interim data which indicated its lead drug can be administered in at least two higher-strength doses.

This has a knock-on positive impact for the imminent phase III clinical trial of MED2002, which is hoped will rubber stamp its huge potential.

Quick facts: Futura Medical PLC

Price: 14.5 GBX

AIM:FUM
Market: AIM
Market Cap: £35.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Futura Medical announce regulatory and commercial progress on erectile...

Futura Medical PLC's (LON:FUM) James Barder talks to Proactive London's Katie Pilbeam about the announcement made today on the regulatory progress in the US. Barder also hints upon significant commercial interest for its erectile dysfunction gel with talks ongoing with a growing number of...

on 22/10/20

2 min read